To develop P3 medicine for T2D, T2DSystems brings together a consortium of leading European researchers, with diverse and highly complementary expertise in the pathogenesis of human T2D, human islets and pancreatic beta cells, genetics, genomics, transcriptomics, metabolomics, systems biology, supercomputing and relational database and algorithm development, industrial expertise in commercial data mining and molecular analysis, in vivo pancreatic beta cell pathophysiology, metabolic phenotyping, T2D treatment and patient stratification. The integration of this expertise will allow the T2DSystems partners to drive forward the discovery of a new molecular taxonomy of T2D and translate this into personalised preventive and therapeutic approaches for T2D in the course of the T2DSystems project.

The T2DSystems consortium has the following specific objectives:

- To compile and expand existing human islet biobanks and datasets from the major European islet research centres, thereby creating the Translational human pancreatic Islet Genotype tissue-Expression Resource (TIGER)


- TIGER will contain genetic, functional genomic, epigenomic, transcriptomic, proteomic and metabolomic human islet data from more than 1400 subjects with a broad spectrum of age, sex, genome-wide genotypes and glucose tolerance. TIGER will represent a unique T2D systems biomedicine relational resource that will combine clinical, genetic and molecular data at an unprecedented scale. This holds the promise to change the map of T2D research and diabetes research in general. It will be available to the T2DSystems partners by month 18 and will be publicly accessible to the research community by month 36 of the project.

- To develop powerful large-scale data fusion and analysis tools to exploit TIGER data towards system-level biological insight